Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Battling the bugs

June 19, 2006 | A version of this story appeared in Volume 84, Issue 25

Your story on modified vancomycin (C&EN, Feb. 13, page 15) stated that "Bacteria such as Staphylococcus aureus ... have developed resistance to a number of antibiotics but not to vancomycin-yet." Sadly, your report is behind the times. Pathogenic Enterococcus that were resistant to vancomycin appeared in our hospitals as early as 1988, and the first report of resistant Staphylococcus aureus appeared in 2003. A search on Medline for "vancomycin resistant Staphylococcus aureus" returns 67 hits. It's like a runaway train. The work of Crowley and Boger is important and encouraging, but it won't be enough. The bugs are winning.

Dexter B. Northrop
Madison, Wis.

CORRECTIONS

May 22, page 34. The instrument pictured should have been identified as a Dionex high-performance liquid chromatography (HPLC) system, not a gas chromatograph and mass spectrometer.

May 29, page 11. Dow Chemical's R&D spending for 2005 was $1.1 billion.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.